Company Overview - ICU Medical, founded in 1984, specializes in developing and manufacturing medical products for infusion therapy, vascular access, and vital care applications used in healthcare settings [3]. Q3 CY2025 Financial Performance - ICU Medical reported Q3 CY2025 revenue of $537 million, which represents an 8.9% decline year on year but exceeded Wall Street's expectations by 4.8% [6][7]. - The non-GAAP profit was $2.03 per share, surpassing analysts' consensus estimates by 41.6% [6]. - Adjusted EBITDA for the quarter was $105.9 million, with a margin of 19.7%, also beating analyst estimates [6]. - The operating margin decreased to 2.6% from 3.6% in the same quarter last year, while the free cash flow margin improved to 5.1% from 2.7% [6]. Revenue Growth Trends - Over the past five years, ICU Medical achieved a compounded annual growth rate of 12.9%, outperforming the average healthcare company [4]. - However, the annualized revenue growth over the last two years was only 1.6%, indicating a slowdown compared to the five-year trend [5]. - Analysts project a further revenue decline of 7.8% over the next 12 months, suggesting potential demand challenges for the company's products and services [7]. Guidance and Market Capitalization - The adjusted EPS guidance for the full year is set at $7.50 at the midpoint, exceeding analyst estimates by 7.3% [6]. - Full-year EBITDA guidance is projected at $400 million, above analyst expectations of $384.8 million [6]. - The current market capitalization of ICU Medical stands at $3.14 billion [6].